Press release
Mucopolysaccharidosis Type I Pipeline Shows Strong Momentum as 8+ Pharma Companies in the Race | DelveInsight
Discover the latest drugs and treatment options in the Mucopolysaccharidosis Type I Pipeline @ https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Mucopolysaccharidosis Type I Pipeline Report
* DelveInsight's Mucopolysaccharidosis Type I Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Mucopolysaccharidosis Type I treatment.
* The leading Mucopolysaccharidosis Type I Companies such as Orchard Therapeutics, JCR Pharmaceuticals, REGENXBIO and others.
* Promising Mucopolysaccharidosis Type I Pipeline Therapies such as Laronidase, Antihistamine, Antipyretic, JR-171, AGT-181, Cyclosporine A (CsA), Azathioprine (Aza), RGX-111, SBC-103 , and others.
Stay ahead with the most recent pipeline outlook for Mucopolysaccharidosis Type I @ Mucopolysaccharidosis Type I Treatment Drugs [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Mucopolysaccharidosis Type I Overview
Mucopolysaccharidosis Type I (MPS I) is a rare genetic disorder that falls under the larger group of lysosomal storage diseases. It is caused by a deficiency of the enzyme alpha-L-iduronidase, which is crucial for breaking down glycosaminoglycans (GAGs), previously known as mucopolysaccharides. The accumulation of GAGs in various tissues and organs leads to the symptoms and complications associated with MPS I. The disorder can present in a spectrum of severity, traditionally classified into three subtypes: Hurler syndrome (severe), Hurler-Scheie syndrome (intermediate), and Scheie syndrome (mild).
Mucopolysaccharidosis Type I Emerging Drugs Profile
* OTL 203: Orchard Therapeutics
OTL-203 is an investigational ex vivo autologous gene therapy being investigated for the treatment of MPS-I. It uses a modified virus to insert a functional copy of the IDUA gene into a patient's cells. OTL-203 is being developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. OTL-203 has received rare pediatric disease designation from the FDA. Through an ongoing proof-of-concept clinical trial, OTL-203 is being evaluated as a potential treatment for patients with the most severe form of MPS-I, known as Hurler syndrome. OTL-203 is an investigational therapy and has not been approved by any regulatory agency or health authority. Currently, the drug is in Phase III stage of its development for the treatment of Mucopolysaccharidosis Type I.
* JR 171: JCR Pharmaceuticals
JR-171, is an investigational drug for the treatment of mucoplysaccharidosis type I (MPS I, or Hurler, Hurler-Scheie and Scheie syndrome). JR-171 is a blood-brain-barrier (BBB)-penetrating form recombinant -L-iduronidase that was developed using JCR's proprietary J-Brain Cargo Registered BBB technology. JR-171 received the orphan drug designation from the US Food Drug Administration (FDA) in February 2021. The trial is also scheduled for enrolling patients in the US. Currently, the drug is in Phase I/II stage of its development for the treatment of Mucopolysaccharidosis Type I.
The Mucopolysaccharidosis Type I Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Mucopolysaccharidosis Type I with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mucopolysaccharidosis Type I Treatment.
* Mucopolysaccharidosis Type I Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Mucopolysaccharidosis Type I Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mucopolysaccharidosis Type I market
Explore groundbreaking therapies and clinical trials in the Mucopolysaccharidosis Type I Marketed and Pipeline Drugs @ New Mucopolysaccharidosis Type I Drugs [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Mucopolysaccharidosis Type I Companies
Orchard Therapeutics, JCR Pharmaceuticals, REGENXBIO and others.
Mucopolysaccharidosis type I (MPS I) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Mucopolysaccharidosis Type I Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Learn about new drugs, pipeline developments with DelveInsight's expert analysis @ Mucopolysaccharidosis Type I Market Drivers and Barriers [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Mucopolysaccharidosis Type I Market Report
* Coverage- Global
* Mucopolysaccharidosis Type I Companies- Orchard Therapeutics, JCR Pharmaceuticals, REGENXBIO and others.
* Mucopolysaccharidosis Type I Pipeline Therapies- Laronidase, Antihistamine, Antipyretic, JR-171, AGT-181, Cyclosporine A (CsA), Azathioprine (Aza), RGX-111, SBC-103 , and others.
* Mucopolysaccharidosis Type I Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Mucopolysaccharidosis Type I Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Mucopolysaccharidosis Type I Therapies and clinical trials @ Mucopolysaccharidosis Type I Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Mucopolysaccharidosis type I (MPS I): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Mucopolysaccharidosis type I (MPS I)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* OTL 203: Orchard Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* JR 171: JCR Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Mucopolysaccharidosis type I (MPS I) Key Companies
* Mucopolysaccharidosis type I (MPS I) Key Products
* Mucopolysaccharidosis type I (MPS I)- Unmet Needs
* Mucopolysaccharidosis type I (MPS I)- Market Drivers and Barriers
* Mucopolysaccharidosis type I (MPS I)- Future Perspectives and Conclusion
* Mucopolysaccharidosis type I (MPS I) Analyst Views
* Mucopolysaccharidosis type I (MPS I) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mucopolysaccharidosis-type-i-pipeline-shows-strong-momentum-as-8-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mucopolysaccharidosis-type-i-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mucopolysaccharidosis Type I Pipeline Shows Strong Momentum as 8+ Pharma Companies in the Race | DelveInsight here
News-ID: 4561241 • Views: …
More Releases from ABNewswire
PursuitCI Ranks 500+ Certifications by What They Actually Pay - and Makes It Fre …
New career intelligence platform publishes salary lift, cost and employer demand for professional credentials, then provides the practice quizzes to earn them and the live jobs hiring for them.
Image: https://www.abnewswire.com/upload/2026/07/8b8da11162433d3fc14ddc451779856f.jpg
Orlando, FL - Every year, millions of working professionals are told the same thing: get certified. Almost none of them are told which one.
A professional certification can cost a four-figure exam fee and six months of nights and weekends. Yet the…
Constar Publishes Distributor's Guide to Vetting Contact Lens Manufacturers on C …
Dual-certified Chinese manufacturer shares a three-pillar framework to help global distributors avoid costly sourcing mistakes.
BAIYIN, GANSU - July 29, 2026 - Distributors entering the contact lens market face a critical challenge: selecting a manufacturing partner that meets regulatory requirements, delivers consistent product quality and maintains reliable production timelines. Getting any one of these wrong can result in seized shipments, customer returns or lost retail windows.
Image: https://www.abnewswire.com/upload/2026/07/1372d6aea7fb3f539e4ecb2b6ecf5007.jpg
Gansu Constar Technology Group [https://www.constarfactory.com/],…
AMMPS.co Expands Operations to Offer Custom LED Truck Fabrication alongside Mobi …
TAMPA, FL - AMMPS.co, a leading visual media and commercial signage firm led by industry veteran Robert (Jay) Vargo, announced today the expansion of its capabilities to include custom LED truck engineering and build-outs. Drawing on decades of hands-on expertise, Vargo leads a company providing a complete ecosystem for mobile advertising and storefront branding-ranging from turn-key custom vehicle builds to fleet rentals and architectural signage.
Under Vargo's leadership, AMMPS.co serves businesses,…
Southwest Gases Accepts New Helium Customers Across Texas Amid Ongoing Supply Ch …
Regional distributor's diversified sourcing strategy enables continued acceptance of new commercial helium customers.
FLOWER MOUND, Texas - Southwest Gases, a regional industrial gas distributor headquartered in Flower Mound, Texas, announced today that it continues to accept new commercial helium customers across Dallas, Houston, Austin, San Antonio, and Fort Worth despite ongoing supply challenges affecting portions of the U.S. helium market.
Over recent months, the helium industry has experienced supply constraints, allocation adjustments,…
More Releases for Mucopolysaccharidosis
Leading Companies Fueling Innovation and Growth in the Mucopolysaccharidosis Tre …
The mucopolysaccharidosis treatment market is on track for significant expansion in the coming years, fueled by rapid advancements in medical research and growing healthcare investments. This market is set to undergo transformative changes as new therapies emerge and diagnostic methods improve, paving the way for better patient outcomes in rare genetic disorders.
Projected Market Size and Growth Prospects for the Mucopolysaccharidosis Treatment Market
By 2030, the mucopolysaccharidosis treatment market is expected…
Mucopolysaccharidosis Treatment Market Trends That Will Shape the Next Decade: I …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Mucopolysaccharidosis Treatment Market Size By 2025?
The market for treatments for mucopolysaccharidosis has experienced robust expansion recently, projected to climb from a valuation of $2.4 billion in 2024 to $2.58 billion by 2025, reflecting a compound annual growth rate of 7.7%; this uptrend during the…
Mucopolysaccharidosis Market Set to Hit USD 3.65 Billion by 2034
Mucopolysaccharidosis (MPS) is a group of rare, inherited metabolic disorders caused by the absence or malfunction of enzymes needed to break down glycosaminoglycans (GAGs). These conditions, including Hurler syndrome (MPS I), Hunter syndrome (MPS II), Sanfilippo syndrome (MPS III), and others, are progressive and can affect physical and cognitive development.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71067
Over the past decade, orphan drug development, advancements in enzyme replacement therapy…
Mucopolysaccharidosis Treatment Market Analysis, Keyplayers, Share And Forecast …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Mucopolysaccharidosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.19 billion In 2028 At…
Mucopolysaccharidosis Treatment Market Size, Trends, Leading Players, Share And …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through Mucopolysaccharidosis Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The mucopolysaccharidosis treatment market size has grown strongly in recent years. It…
Gene Therapy for Mucopolysaccharidosis Market to Witness Growth Acceleration by …
Gene Therapy for Mucopolysaccharidosis Market is expected to witness moderate growth registering 9.4% CAGR during the forecast period (2023-2029).
Important changes in the business allow key players to attain larger profits. This Gene Therapy for Mucopolysaccharidosis Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry. Furthermore, this market report makes…
